Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: Results of a randomized controlled trial

Cancer

Volumn 110, Issue 11, 2007, Pages 2448-2457

  Negrier, Sylvie ^a,b   Perol, David ^b   Ravaud, Alain ^c   Chevreau, Christine ^d   Bay, Jacques Olivier ^e   Delva, Remy ^f   Sevin, Emmanuel ^g   Caty, Armelle ^h   Escudier, Bernard ⁱ  

^a UNIVERSITÉ DE LYON   (France)

^b CENTRE LÉON BÉRARD   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e CENTRE JEAN PERRIN   (France)

^f CENTRE PAUL PAPIN   (France)

^g Cancer Institute   (France)

^h CENTRE OSCAR LAMBRET   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

IFN; IL 2; Interferon alfa; Interleukin 2; Metastatic renal cancer; Survival

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; INTERLEUKIN 2; MEDROXYPROGESTERONE ACETATE; SORAFENIB;

ADULT; AGED; ANEMIA; ARTICLE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; FEMALE; FEVER; FOLLOW UP; HEART DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG DISEASE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NEUROLOGIC DISEASE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

EID: 36448930484     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23056     Document Type: Article

References (35)

1. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol. 1995;22:42-60.
2. Lilleby W, Fossa SD. Chemotherapy in metastatic renal cell cancer. World J Urol. 2005;23:175-179.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
4. Coppin C, Porzsolt F, Kumpf J, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1:CD001425; 2005.
5. Medical Research Council Renal Cancer Collaborators: Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999;353:14-17.
6. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859-2867.
7. Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology. 1995;45:758-762.
8. Steineck G, Strander H, Carbin BE, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol. 1990;29:155-162.
9. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med. 1998;338:1272-1278.
10. Negrier S, Gomez F, Douillard JY, et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. World J Urol. 2005;23:161-165.
11. Green S, Liu PY, O'Sullivan J. Factorial design considerations. J Clin Oncol. 2002;20:3424-3430.
12. Freedman LS. Tables of the number of patients required in clinical trials using the log rank test. Stat Med. 1983;1:121-129.
13. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
14. Common Toxicity Criteria version 2.0. Bethesda, Md: National Institutes of Health, National Cancer Institute; March 1998.
15. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1-39.
18. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Ser B. 1972;34:187-202.
19. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343-346.
20. Fayers PM. Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur J Cancer. 2001;37:1331-1334.
21. Therneau T, Grambsch P. Modeling survival data: extending the Cox model. New York: Springer-Verlag; 2000.
22. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
23. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889-897.
24. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132.
25. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.
26. Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer. 2001;85:1130-1136.
27. Henriksson R, Nilsson S, Colleen S, et al. Survival in renal cell carcinoma - a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen. Br J Cancer. 1998;77:1311-1317.
28. Lummen G, Goepel M, Mollhoff S, et al. Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma. J Urol. 1996;155:455-458.
29. Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2 - and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol. 2004;22:1188-1194.
30. Boccardo F, Rubagotti A, Canobbio L, et al. Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial. Tumori. 1998;84:534-539.
31. Atzpodien J, Schmitt E, Gertenbach U, et al. Adjuvant treatment with interleukin-2 - and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer. 2005;92:843-846.
32. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21:3133-3140.
33. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001;19:425-431.
34. Porzsolt F. Adjuvant therapy of renal cell cancer with interferon alpha-2a [abstract]. Proc Am Soc Clin Oncol. 1992;11:202. Abstract 622.
35. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003;21:1214-1222.